Search results for "C25"

showing 10 items of 566 documents

Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

2021

<b><i>Introduction:</i></b> The prognosis of patients undergoing transarterial chemoembolization (TACE) is extremely variable, and a confounding factor is that TACE is often repeated several times. We retrospectively evaluated the accuracy of different prognostic scores and staging systems in estimating overall survival (OS) in patients with hepatocellular carcinoma (HCC). <b><i>Methods:</i></b> An analysis considering prognostic models as time-varying variables was performed, calculating OS from the time of TACE to the time of the subsequent treatment. Total follow-up time for each patient was therefore split into several observation times ac…

ALBI grade; Barcelona Clinic Liver Cancer; Cancer of the Liver Italian Program; ITALICA staging system; MESIAHmedicine.medical_specialtylcsh:RC254-282GastroenterologyALBI gradeBarcelona Clinic Liver CancerInternal medicineMedicineIn patientCancer of the Liver Italian ProgramITALICA staging systemRadiologic ResponseSettore MED/12 - GastroenterologiaOriginal PaperHepatologybusiness.industryProportional hazards modelConfoundingHazard ratiolcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMESIAHOncologyHepatocellular carcinomaAkaike information criterionbusinessLiver cancer
researchProduct

Acute Promyelocytic Leukemia during Pregnancy: A Systematic Review of the Literature

2020

The management of pregnant women with acute promyelocytic leukemia (APL) is a challenging situation where limited evidence-based information is available. We performed a systematic literature review to analyze the outcomes reported for both mother and fetus when APL is diagnosed during pregnancy. PubMed, Scopus and Web of Science databases were systematically searched to identify studies reporting cases of APL during pregnancy. Sixty-six articles met the eligibility criteria (53 single case reports). Ninety-two patients were eligible for induction therapy, with most them being treated with all-trans retinoic acid alone (32%) or combined with chemotherapy (43%), while the remaining patients …

Acute promyelocytic leukemiaCancer Researchmedicine.medical_specialtyAbortionchemotherapylcsh:RC254-282Article03 medical and health sciences0302 clinical medicineObstetrics and gynaecologymedicineNeonatologyPregnancyFetal viabilityRespiratory distressObstetricsbusiness.industryGestational ageacute promyelocytic leukemialcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseall-trans retinoic acidarsenic trioxideOncology030220 oncology & carcinogenesispregnancybusiness030215 immunologyCancers
researchProduct

Genotypic and Phenotypic Characteristics of Acute Promyelocytic Leukemia Translocation Variants.

2020

Acute promyelocytic leukemia (APL) is a special disease entity of acute myeloid leukemia (AML). The clinical use of all-trans retinoic acid (ATRA) has transformed APL into the most curable form of AML. The majority of APL cases are characterized by the fusion gene PML-RARA. Although the PML-RARA fusion gene can be detected in almost all APL cases, translocation variants of APL have been reported. To date, this is the most comprehensive review of these translocations, discussing 15 different variants. Reviewed genes involved in APL variants include: ZBTB16, NPM, NuMA, STAT5b, PRKAR1A, FIP1L1, BCOR, NABP1, TBLR1, GTF2I, IRF2BP2, FNDC3B, ADAMDTS17, STAT3, and TFG. The genotypic and phenotypic …

Acute promyelocytic leukemiaGenotypeSTAT5BChromosomal translocationFusion geneslcsh:RC254-282Translocation GeneticFusion gene03 medical and health sciences0302 clinical medicineLeukemia Promyelocytic AcuteAcute promyelocytic leukemiaimmune system diseasesMedicineHumansneoplasmsPRKAR1AGeneRARAlcsh:RC633-647.5business.industryMyeloid leukemialcsh:Diseases of the blood and blood-forming organsHematologyGeneral Medicinelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseFusion proteinNeoplasm ProteinsOncology030220 oncology & carcinogenesisCancer researchbusinessChimeric proteins030215 immunologyHematology/oncology and stem cell therapy
researchProduct

Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma

2017

Abstract Background Transarterial chemoembolisation is the standard of care for intermediate stage (BCLC B) hepatocellular carcinoma, but it is challenging to decide when to repeat or stop treatment. Here we performed the first external validation of the SNACOR (tumour Size and Number, baseline Alpha-fetoprotein, Child-Pugh and Objective radiological Response) risk prediction model. Methods A total of 1030 patients with hepatocellular carcinoma underwent transarterial chemoembolisation at our tertiary referral centre from January 2000 to December 2016. We determined the following variables that were needed to calculate the SNACOR at baseline: tumour size and number, alpha-fetoprotein level,…

AdultAged 80 and overMaleCarcinoma HepatocellularHepatocellular carcinomaLiver Neoplasms610 MedizinKaplan-Meier EstimateSNACORMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282Magnetic Resonance ImagingTreatment OutcomeTransarterial chemoembolisation610 Medical sciencesBiomarkers TumorHumansFemaleChemoembolization TherapeuticTomography X-Ray ComputedAgedNeoplasm StagingResearch Article
researchProduct

Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

2021

AbstractThere is evidence of reduced SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies. We hypothesized that tumor and treatment-related immunosuppression can be depicted in peripheral blood, and that immune profiling prior to vaccination can help predict immunogenicity. We performed a comprehensive immunological characterization of 83 hematological patients before vaccination and measured IgM, IgG, and IgA antibody response to four viral antigens at day +7 after second-dose COVID-19 vaccination using multidimensional and computational flow cytometry. Health care practitioners of similar age were the control group (n = 102). Forty-four out of 59 immune cell types …

AdultAged 80 and overMaleHaematological cancerCOVID-19 VaccinesSARS-CoV-2COVID-19Vaccine EfficacyNeoplasms. Tumors. Oncology. Including cancer and carcinogenslymphomaHematologyMiddle Agedhematologic malignancieArticleImmunocompromised HostmyelomaOncologyHematologic NeoplasmsHumansTumour immunologyFemaleSars-cov-BiomarkersRC254-282AgedBlood Cancer Journal
researchProduct

Unravelling the heterogeneity of soft tissue and bone sarcoma patients’ health-related quality of life: a systematic literature review with focus on …

2020

Contains fulltext : 229532.pdf (Publisher’s version ) (Open Access) Patients with sarcoma experience many physical and psychological symptoms, adversely affecting their health-related quality of life (HRQoL). HRQoL assessment is challenging due to the diversity of the disease. This review aims to unravel the heterogeneity of HRQoL of patients with sarcoma with regard to tumour location and to summarise the used measures in research. English-language literature from four databases published between January 2000 and April 2019 was reviewed. Studies that described adult sarcoma HRQoL outcomes were included and classified according to primary sarcoma location. Eighty-seven articles met the incl…

AdultCancer Researchmedicine.medical_specialtyConstitutional symptomsPopulationbone sarcomaSoft Tissue NeoplasmsReviewBone Sarcomalcsh:RC254-282Quality of lifeInternal medicineSurveys and QuestionnairesMedicineHumans1506educationeducation.field_of_studyOsteosarcomabusiness.industrySoft tissue sarcomaSarcomamedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenshumanitieshealth-related quality of lifeSystematic reviewOncologypatient-reported outcomessoft tissue sarcomaQuality of LifeSarcomabusinessPsychosocialRare cancers Radboud Institute for Health Sciences [Radboudumc 9]ESMO Open
researchProduct

Primitive Neuroectodermal Tumor (PNET) of the kidney: a case report.

2004

Abstract Background A case of Primitive Neuroectodermal Tumor (PNET) of the kidney in a 27-year-old woman is presented. Few cases are reported in the literature with a variable, nonspecific presentation and an aggressive behaviour. In our case, a radical nephrectomy with lymphadenectomy was performed and there was no residual or recurrent tumour at 24-month follow-up. Methods The surgical specimens were formalin-fixed and paraffin embedded. The sections were stained with routinary H&E. Immunohistochemistry was performed. Results The immunohistochemical evaluation revealed a diffuse CD99 positivity in the cytoplasm of the neoplastic cells. Pankeratin, cytokeratin AE1/AE3, vimentin, desmin, S…

AdultEwing's SarcomaPNETCancer ResearchPathologymedicine.medical_specialtyRenal PNETmedicine.medical_treatmentCD99Case Reportlcsh:RC254-282Diagnosis DifferentialCytokeratinImmunophenotypingSurgical oncologystem cellsGeneticsmedicineHumansNeuroectodermal Tumors Primitive Peripheralrhabdomyosarcoma tumorbusiness.industryEwing's sarcomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseNephrectomyKidney NeoplasmsOncologyPrimitive neuroectodermal tumorFemaleDifferential diagnosisbusinesscarcinogenesis
researchProduct

Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis.

2015

Background and Aim. The best staining to evaluate liver fibrosis in liver hepatitis is still a debated topic. This study aimed to compare Masson’s trichrome (MT), Sirius Red (SR), and orcein stainings in evaluating liver fibrosis in chronic HCV hepatitis (CHC) with semiquantitative and quantitative methods (Collagen Proportionate Area (CPA) by Digital Image Analysis (DIA)) and correlate them with transient elastography (TE).Methods. Liver stiffness evaluation of 111 consecutive patients with CHC was performed by TE. Semiquantitative staging by Metavir score system and CPA by DIA were assessed on liver biopsy stained with MT, SR, and orcein.Results. MT, SR, and orcein staining showed concord…

AdultLiver CirrhosisMaleCancer ResearchPathologymedicine.medical_specialtyArticle SubjectAdolescentliver fibrosis elastography Digital Image Analysis liver biopsySettore MED/08 - Anatomia PatologicaPathology and Forensic Medicinechemistry.chemical_compoundYoung AdultTrichromeFibrosisImage Processing Computer-AssistedMedicineHumansOrceinSirius RedRC254-282AgedHepatitis ChronicHepatitisSettore MED/12 - Gastroenterologiamedicine.diagnostic_testQH573-671Staining and Labelingbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseStainingchemistryLiver biopsyMolecular MedicineElasticity Imaging TechniquesFemalebusinessTransient elastographyCytologyResearch ArticleAnalytical cellular pathology (Amsterdam)
researchProduct

Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of…

2020

BackgroundImmune checkpoint inhibition (ICI) is an essential treatment option in melanoma. Its outcome may be improved by a preceding radiation of metastases. This study aimed to investigate the impact of a preceding radiotherapy on the clinical outcome of ICI treatment.MethodsThis multicenter retrospective cohort study included patients who received anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or anti-programmed cell death protein 1 (PD-1) ICI with or without preceding radiotherapy for unresectable metastatic melanoma. ICI therapy outcome was measured as best overall response (BOR), progression-free (PFS) and overall survival (OS). Response and survival analyses were adjusted …

AdultMale0301 basic medicineOncologyCancer Researchmedicine.medical_specialtySkin NeoplasmsMetastatic melanoma2435medicine.medical_treatmentProgrammed Cell Death 1 ReceptorImmunologyMedizin03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansImmunology and AllergyCTLA-4 Antigen1506Immune Checkpoint InhibitorsMelanomaradiotherapyRC254-282Survival analysisRetrospective StudiesClinical/Translational Cancer ImmunotherapyPharmacologybusiness.industryMelanomaConfoundingNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studyChemoradiotherapyMiddle Agedmedicine.diseaseProgression-Free SurvivalImmune checkpointRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesisRelative riskMolecular MedicineFemalebusinessJournal for ImmunoTherapy of Cancer
researchProduct

Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial

2018

Background:Gastric cancer is common malignancy and exhibits a poor prognosis. At the time of diagnosis, the majority of patients present with metastatic disease which precludes curative treatment. Non-invasive biomarkers which discriminate early from advanced stages or predict the response to treatment are urgently required. This study explored the cytokeratin-18 fragment M30 and full-length cytokeratin-18 M65 in predicting treatment response and survival in a randomized, placebo-controlled trial of advanced gastric cancer.Methods:Patients enrolled in the SUN-CASE study received sunitinib or placebo as an adjunct to standard therapy with leucovorin (Ca-folinate), 5-fluorouracil, and irinote…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyIndolesmedicine.medical_treatmentLeucovorinAntineoplastic AgentsPlaceboDisease-Free SurvivalMetastasislaw.inventionPlacebos03 medical and health sciences0302 clinical medicineRandomized controlled trialStomach NeoplasmslawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorSunitinibHumansMedicinePyrrolesProgression-free survivalRC254-282AgedAged 80 and overChemotherapyKeratin-18business.industrySunitinibCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineMiddle Agedmedicine.diseasePeptide FragmentsIrinotecan030104 developmental biology030220 oncology & carcinogenesisCamptothecinFemaleFluorouracilbusinessmedicine.drugTumor Biology
researchProduct